Subtitle: Market Intelligence, Early-Stage Progress, and High-Purity Reagents for Metabolic Disease R&D.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NPY4R2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NPY4R2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View NPY4R2 Products |
| Gene Delivery | NPY4R2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Optimal for GPCRs. |
View NPY4R2 Products |
| Benchmark Ab | Anti-NPY4R2 Research Control Recombinant positive control for assay development. |
View NPY4R2 Products |
| Validator | NPY4R2 siRNA Set For knockdown verification and specificity profiling. |
View NPY4R2 Products |
| Related Target A | NPY1R Homologous family member for selectivity counter-screening. |
View NPY1R Products |
| Related Target B | NPY2R Synergistic metabolic pathway receptor. |
View NPY2R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Maintenance | Lentivirus premade particles for stable cell line generation (Flow Cytometry/Calcium Flux ready) |
| NPY Receptor Subfamily Cross-reactivity | Sequence Verified homolog panels (NPY1R, NPY2R, NPY5R) available for stringent selectivity screening |
| Lack of Reliable Controls | Sequence-verified recombinant tool antibodies included for assay benchmarking |
| Target Specificity Validation | Validated siRNA sets included for orthogonal specificity checks |
Live NPY4R2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Preclinical Landscape & Future Outlook
Research into the Neuropeptide Y (NPY) receptor family, including NPY4R2, is primarily focused on their roles in appetite regulation, energy homeostasis, and metabolic disorders. While targets like NPY1R and NPY5R have historically drawn attention, specialized variants and related receptors like NPY4R2 represent exploratory frontiers. The current landscape is heavily preclinical, with researchers focusing on understanding ligand specificity and functional differentiation from the broader NPY receptor family. Future R&D will likely hinge on developing highly selective modulators that avoid off-target metabolic effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Agonists | Academic/Early Biotech | Obesity / Metabolic Syndrome | Receptor Activation (Need Lentivirus for Cell Lines) |
| Small Molecules | Discovery Stage | Metabolic Disorders | Selectivity Assay (Need Homolog Cell Lines) |
| Tool Antibodies | Research Reagents | Basic Biology | Binding Assays (Need High-Purity Antigens) |